|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.45 USD | +1.37% |
|
-6.32% | -32.78% |
| Apr. 15 | TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR | CI |
| Mar. 22 | Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating | MT |
TELA Bio, Inc. provided revenue guidance for the full year 2024. Full year 2024 revenue is projected to range from $74.0 million to $76.0 million, representing growth of 27% to 30% over full year 2023.
| 1st Jan change | Capi. | |
|---|---|---|
| -32.78% | 110M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.36% | 26.25B | |
| +2.07% | 26.48B | |
| +12.96% | 24.62B |
TELA BIO, INC. 
